The interest of molecular biology in both diagnosis, prognosis and treatment in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 is obvious since specific targeted therapies are already available and used both in chronic myeloid leukemia (CML) and AML, with a drastic improvement of prognosis, more particularly for patients unfit for allogeneic stem cell transplantation. Here, BCR is linked to acute myeloid leukemia.